Rasagiline – a novel MAO B inhibitor in Parkinson's disease ... | 合法藥品大搜索

Read More

PD cellular pathological mechanisms · 由 S Lecht 著作 · 2007 · 被引用 54 次 — The complexity of pathological mechanisms is a significant obstacle in effective treatment of the disease. Read More

Mechanism of action — Mechanism of action[edit]. Parkinson's disease is characterized by the death of cells that produce dopamine, a neurotransmitter. An ... Read More

The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an ... Read More

由 S Mandel 著作 · 2005 · 被引用 190 次 — Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor, anti-Parkinson drug. Unlike selegiline, ... Read More

由 W Maruyama 著作 · 2000 · 被引用 97 次 — Rasagiline protected in vitro dopamine cells from apoptosis induced by oxidative stress or neurotoxins. The mechanism of the anti-apoptotic effect was studied ... Read More

由 O Weinreb 著作 · 2005 · 被引用 79 次 — Our studies have provided new insights into the biological mechanism of neuroprotection of the anti-Parkinson drug, rasagiline [N-propargyl-(1R)-aminoindan] ... Read More

由 M Naoi 著作 · 2013 · 被引用 42 次 — In cellular and animal models, selegiline [(-)deprenyl] and rasagiline, ... and selegiline: the induction of distinct genes by different mechanisms. Read More

由 O Weinreb 著作 · 2010 · 被引用 177 次 — Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor. However, both compounds have similar molecular mechanisms of neuroprotection in ... Read More

Rasagiline's exact mechanism of action is not known; however, by inhibiting MAO-B rasagiline reduces the breakdown of dopamine resulting in increased levels of ... Read More